12:00 AM
 | 
Nov 10, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Telaprevir: Additional Phase IIa data

Additional data from the open-label Phase IIa C208 study showed that 1,125 mg of twice-daily telaprevir plus Copegus ribavirin and either Pegasys peginterferon alfa-2a or PEG-Intron peginterferon alfa-2b produced 83% and 85% rates of undetectable HCV RNA (<10 IU/mL)...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >